DK1937827T3 - Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SOD - Google Patents

Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SOD

Info

Publication number
DK1937827T3
DK1937827T3 DK06790622.2T DK06790622T DK1937827T3 DK 1937827 T3 DK1937827 T3 DK 1937827T3 DK 06790622 T DK06790622 T DK 06790622T DK 1937827 T3 DK1937827 T3 DK 1937827T3
Authority
DK
Denmark
Prior art keywords
antibody
diagnosis
prevention
treatment
sod
Prior art date
Application number
DK06790622.2T
Other languages
English (en)
Inventor
Jean-Pierre Julien
Makoto Urushitani
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of DK1937827T3 publication Critical patent/DK1937827T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90283Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
DK06790622.2T 2005-08-31 2006-08-31 Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SOD DK1937827T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71240005P 2005-08-31 2005-08-31
PCT/CA2006/001444 WO2007025385A1 (en) 2005-08-31 2006-08-31 Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities

Publications (1)

Publication Number Publication Date
DK1937827T3 true DK1937827T3 (da) 2012-01-23

Family

ID=37808437

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06790622.2T DK1937827T3 (da) 2005-08-31 2006-08-31 Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SOD

Country Status (8)

Country Link
US (2) US8759029B2 (da)
EP (1) EP1937827B1 (da)
JP (1) JP5242396B2 (da)
AT (1) ATE526345T1 (da)
CA (1) CA2620351C (da)
DK (1) DK1937827T3 (da)
ES (1) ES2374102T3 (da)
WO (1) WO2007025385A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4668191B2 (ja) 2003-08-20 2011-04-13 アモールフィックス・ライフ・サイエンシィズ・リミテッド タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法
US7887803B2 (en) 2005-12-02 2011-02-15 Amorfix Life Sciences Methods and compositions to treat misfolded-SOD1 mediated diseases
US7794692B2 (en) 2005-12-02 2010-09-14 Amorfix Life Sciences Ltd. Methods and compositions for detecting amyotrophic lateral sclerosis
EP2502999A3 (en) * 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
WO2010056732A1 (en) 2008-11-12 2010-05-20 Marv Enterprises Llc Utilization of stents for the treatment of blood borne carcinomas
US9216386B2 (en) * 2009-03-17 2015-12-22 Marv Enterprises, LLC Sequential extracorporeal treatment of bodily fluids
EP2483407A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2011142461A1 (ja) * 2010-05-13 2011-11-17 国立大学法人 東京大学 筋萎縮性側索硬化症(als)の診断のための抗体
US9109037B2 (en) 2010-10-26 2015-08-18 University Of Massachusetts Anti-SOD1 antibodies and uses thereof
EP3628689A1 (en) 2010-12-17 2020-04-01 Neurimmune Holding AG Human anti-sod1 antibodies
KR20210111242A (ko) 2018-10-29 2021-09-10 바이오젠 엠에이 인코포레이티드 혈액 뇌 장벽 수송을 향상시키기 위한 인간화 및 안정화된 fc5 변이체
WO2023033049A1 (ja) * 2021-09-02 2023-03-09 国立大学法人滋賀医科大学 筋萎縮性側索硬化症の原因となる変異型sod1タンパク質に結合性を有する抗体及び抗体断片
JPWO2023033050A1 (da) * 2021-09-02 2023-03-09
CN113774089A (zh) * 2021-10-11 2021-12-10 深圳大学 肌萎缩侧索硬化细胞模型细胞株的构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940659A (en) 1987-02-20 1990-07-10 Monoclonetics International, Inc. Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome
US5843641A (en) 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
US5780489A (en) 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
US6420429B1 (en) 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
JP4668191B2 (ja) * 2003-08-20 2011-04-13 アモールフィックス・ライフ・サイエンシィズ・リミテッド タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法

Also Published As

Publication number Publication date
JP5242396B2 (ja) 2013-07-24
US20140341927A1 (en) 2014-11-20
ES2374102T3 (es) 2012-02-13
WO2007025385A1 (en) 2007-03-08
US20090068194A1 (en) 2009-03-12
US8759029B2 (en) 2014-06-24
CA2620351A1 (en) 2007-03-08
US9266963B2 (en) 2016-02-23
CA2620351C (en) 2015-04-21
ATE526345T1 (de) 2011-10-15
JP2009507475A (ja) 2009-02-26
EP1937827B1 (en) 2011-09-28
EP1937827A4 (en) 2009-02-18
EP1937827A1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
DK1937827T3 (da) Antistoffer og deres anvendelse til behandling, forebyggelse og diagnose af en sygdom forbundet med SOD
LUC00053I9 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
EP4218794A3 (en) Immunological targeting of pathological tau proteins
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
EA200870050A1 (ru) Анти-il-17-антитела
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
MA30632B1 (fr) Anticorps humanisé
UA92505C2 (ru) Композиции на основе антитела против cd3
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
PH12011502389A1 (en) Monoclonal antibody
PE20100684A1 (es) Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh
MX338421B (es) Anticuerpos fosfoespecificos que reconocen la proteina tau.
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2008150946A8 (en) HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF
TW200709817A (en) Platform antibody compositions
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
EA201992688A1 (ru) Средства, пути применения и способы лечения
SG162829A1 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
CR20140496A (es) Anticuerpos humanizados contra beta-amiloides